With in-house production and manufacturing capacity, as well as a deal with Merck Serono, India-based generics giant Dr. Reddy’s is looking to bring as many as four biosimilars to the EU market by 2019.
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
Outsourcing-Pharma.com presents its latest round up of career moves in the pharmaceutical industry, including news from Theorem, FMC Technologies and EMD Serono.
Biosimilars should help Millipore achieve long-term growth but cancellation of an insulin contract and rising raw material costs hit second quarter results.
The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.
Merck Millipore says Gyros’ Gyrolab xP workstation will be a competitive advantage for its contract immunogenicity, pharmacokinetics and cGMP testing offering for the biopharmaceutical industry.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
Millipore has expanded its microbial detection offering with Milliflex Quantum which, it says, enables manufacturers to respond to contamination issues earlier in the drug and vaccine production process.
German pharmaceutical firm Merck KGaA says proposed Millipore acquisition will transform its chemicals unit and give it a more balanced business profile.
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
Merck KGaA drops plans to build a €300m biomanufacturing plant in
Jena, Germany, on the grounds that late-stage product failures have
left plenty of free capacity in the contract sector. The company's
move suggests that the often-repeated...
